Deal title |
Principal |
Partner |
Total projected at signing (US$M) |
Start date |
May | ||||
Mundipharma to distribute Endoceutics' prasterone in Middle East and Africa |
Endoceutics Inc. |
Mundipharma International Corp. Ltd. |
Payment unspecified |
5/20/18 |
Adaptive and Sanofi to assess minimal residual disease status in response to isatuximab for multiple myeloma using Clonoseq assay |
Adaptive Biotechnologies Corp. |
Sanofi SA |
Payment unspecified |
5/29/18 |
Arix and Evotec to establish a joint venture for cancer and infectious disease drug development |
Arix Bioscience plc |
Evotec AG |
Payment unspecified |
5/31/18 |
Novartis to develop BDD's Oralogik technology for an undisclosed compound |
BDD Pharma Ltd. |
Novartis Pharma AG |
Payment unspecified |
5/30/18 |
Centogene to support Orphazyme's arimoclomol clinical trials for treatment of neuronopathic Gaucher disease in India |
Centogene Gmbh |
Orphazyme Aps |
Payment unspecified |
5/23/18 |
Sun Pharma to commercialize Churchill Pharma's Yonsa for prostate cancer |
Churchill Pharmaceuticals LLC |
Sun Pharmaceutical Industries Ltd. |
Payment unspecified |
5/23/18 |
Clinigen Group to initiate Managed Access Program for MTPC's edaravone in Europe |
Clinigen Group plc |
Mitsubishi Tanabe Pharma Corp. |
Payment unspecified |
5/22/18 |
Clinigen to provide supply and distribution services for Nordic's aprotinin to prevent blood loss in Asia Pacific and South Africa |
Clinigen Group plc |
Nordic Pharma |
Payment unspecified |
5/24/18 |
Clinigen to commercialize Bristol Myers Squibb's products in South Africa |
Clinigen Group plc |
Bristol-Myers Squibb Co. |
Payment unspecified |
5/31/18 |
Cloud Pharmaceuticals to design novel small-molecule agents to GSK specified targets |
Cloud Pharmaceuticals Inc. |
Glaxosmithkline plc |
Payment unspecified |
5/30/18 |
Zai Lab to develop and commercialize Crescendo Biologics' antibody VH domain therapeutic against inflammatory disease worldwide |
Crescendo Biologics Ltd. |
Zai Lab Ltd. |
Payment unspecified |
5/30/18 |
Darman Ara to distribute MDI's products including Penthrox for pain relief in Iran |
Darman Ara Co. |
Medical Developments International Ltd. |
Payment unspecified |
5/29/18 |
Glenmark to manufacture and supply Elite's two generic products |
Elite Pharmaceuticals Inc. |
Glenmark Pharmaceuticals Ltd. |
Payment unspecified |
5/22/18 |
Novo Nordisk to develop and commercialize Epigen's EPGN-696 against diabetic and chronic kidney diseases worldwide |
Epigen Biosciences Inc. |
Novo Nordisk A/S |
$200.00 |
5/23/18 |
FM and Merck to develop pan-cancer companion diagnostic tests for Keytruda |
Foundation Medicine Inc. |
Merck & Co. Inc. |
Payment unspecified |
5/24/18 |
Molmed and Glycostem to enter a binding term sheet to develop and manufacture new natural killer cells-based allogeneic chimeric antigen receptor therapies for cancer |
Glycostem BV |
Molmed SpA |
Payment unspecified |
5/31/18 |
H. Lundbeck divesting two research programs to Mindimmune Therapeutics |
H. Lundbeck A/S |
Mindimmune Therapeutics Inc. |
Payment unspecified |
5/22/18 |
Abcellera and Harbour Antibodies to combine single-cell antibody discovery capabilities and H2L2 transgenic mouse platform for the discovery of antibodies |
Harbour Antibodies BV |
Abcellera Biologics Inc. |
Payment unspecified |
5/30/18 |
Celsius Therapeutics to use Harbour Biomed's H2L2 fully human antibody discovery platform to discover fully human monoclonal antibodies |
Harbour Biomed |
Celsius Therapeutics Inc. |
Payment unspecified |
5/31/18 |
Hitgen to discover compounds for Forma Therapeutics' targets using DNA-encoded libraries worldwide |
Hitgen Ltd. |
Forma Therapeutics Inc. |
Payment unspecified |
5/31/18 |
Shionogi to develop, manufacture and commercialize Hsiri's therapeutics for nontuberculous mycobacteria diseases and tuberculosis worldwide |
Hsiri Therapeutics LLC |
Shionogi & Co. Ltd. |
Payment unspecified |
5/31/18 |
IMV and PCI Biotech to evaluate the formulation compatibility of respective technologies in the field of nucleic acid therapeutics |
IMV Inc. |
PCI Biotech Holding ASA |
Payment unspecified |
5/24/18 |
Pivot to acquire option to use Ip Med's Trivair for the delivery of ready to infuse cannabis products worldwide |
Ip Med Inc. |
Pivot Pharmaceuticals Inc. |
Payment unspecified |
5/31/18 |
Antengene to develop and commercialize Karyopharm's selinexor, eltanexor, KPT-9274 for oncology and verdinexor for non-oncology in China and other regions in Asia |
Karyopharm Therapeutics Inc. |
Antengene Corp. |
$162.00 |
5/23/18 |
Virpax to use Medpharm's Medspray technology to deliver DSF-100 for pain |
Medpharm Ltd. |
Virpax Pharmaceuticals Inc. |
Payment unspecified |
5/29/18 |
Mesoblast and Cartherics to develop allogeneic chimeric antigen receptor T cell-based immunotherapies for solid cancers |
Mesoblast Ltd. |
Cartherics Pty Ltd. |
Payment unspecified |
5/29/18 |
Mitsubishi Chemical, Ono and Daiichi to launch a consortium to discover drugs for intractable immune-mediated inflammatory diseases |
Mitsubishi Chemical Holdings Corp. |
Ono Pharmaceutical Co. Ltd. |
Payment unspecified |
5/30/18 |
Syndax and Nektar to evaluate the combination of NKTR-214 and entinostat for metastatic melanoma |
Nektar Therapeutics |
Syndax Pharmaceuticals Inc. |
Payment unspecified |
5/30/18 |
Oncodna to provide patient enrollment services to Kura Oncology's tipifarnib trial in patients with head and neck squamous cell carcinoma |
Oncodna SA |
Kura Oncology Inc. |
Payment unspecified |
5/22/18 |
Tanner to distribute Partner's Leukine for bone marrow transplantation worldwide, excluding the U.S. and Canada |
Partner Therapeutics Inc. |
Tanner Pharma Group plc |
Payment unspecified |
5/24/18 |
Acerus to commercialize Pharmanest's Shact for pain in Canada |
Pharmanest AB |
Acerus Pharmaceuticals Corp. |
Payment unspecified |
5/31/18 |
Emergent to develop Profectus' Nipah virus vaccine |
Profectus Biosciences Inc. |
Emergent Biosolutions Inc. |
Payment unspecified |
5/24/18 |
Replimune and Regeneron to evaluate RP-1 in combination with cemiplimab against cutaneous squamous-cell carcinoma |
Replimune Group Inc. |
Regeneron Pharmaceuticals Inc. |
Payment unspecified |
5/29/18 |
Rigel to distribute Biologics' Tavalisse for thrombocytopenia |
Rigel Pharmaceuticals Inc. |
Biologics Inc. |
Payment unspecified |
5/29/18 |
Five Prime and Roche to develop immunohistochemistry companion diagnostic assays for use with bemarituzumab and FPA-150 for cancer |
Roche Holding AG |
Five Prime Therapeutics Inc. |
Payment unspecified |
5/30/18 |
Los Altos to develop and commercialize Sedor's CE-Meloxicam for pain in China, Taiwan, Hong Kong and Macau |
Sedor Pharmaceuticals LLC |
Los Altos Pharmaceuticals Inc. |
Payment unspecified |
5/30/18 |
Seed Health to commercialize Optibiotix's LP-LDL products for cholesterol and blood pressure in the U.S. |
Seed Health Inc. |
Optibiotix Health plc |
Payment unspecified |
5/22/18 |
Shuwen to develop companion diagnostics for Bliss' cancer drugs |
Shuwen Biotech Co. Ltd. |
Bliss Biopharmaceutical Co. Ltd. |
Payment unspecified |
5/28/18 |
Oncolys Biopharma to license intellectual property related to Therm-SB from Stabilitech worldwide |
Stabilitech Ltd. |
Oncolys Biopharma Inc. |
Payment unspecified |
5/23/18 |
Aska to develop and commercialize Takeda's relugolix for uterine fibroids and endometriosis in Japan |
Takeda Pharmaceutical Co. Ltd. |
Aska Pharmaceutical Co. Ltd. |
Payment unspecified |
5/31/18 |
Link Health to develop and commercialize Teikoku Pharma's Lidoderm for pain in China |
Teikoku Pharma USA Inc. |
Link Health Group |
Payment unspecified |
5/30/18 |
Antibody Solutions to use Trianni's Mouse in antibody discovery programs |
Trianni Inc. |
Antibody Solutions |
Payment unspecified |
5/22/18 |
Brii Biosciences to acquire greater China rights for up to four infectious disease assets from Vir Biotechnology |
Vir Biotechnology Inc. |
Brii Biosciences |
Payment unspecified |
5/24/18 |
Newsoara to develop and commercialize Vtv Therapeutics' HPP-737 for respiratory and other inflammatory diseases in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries |
Vtv Therapeutics LLC |
Newsoara Biopharma Co. Ltd. |
Payment unspecified |
5/31/18 |
Harbin Pharmaceutical to distribute Wize Pharma's LO2A for ophthalmic disorders in China |
Wize Pharma Inc. |
Harbin Pharmaceutical Group Co. Ltd. |
Payment unspecified |
5/31/18 |
Wuxi Biologics and Bioasis to develop and manufacture Xb-001 against brain cancer |
Wuxi Biologics |
Bioasis Technologies Inc. |
Payment unspecified |
5/21/18 |
Novarock Biotherapeutics to use Trianni's mouse in monoclonal antibody discovery research |
Trianni Inc. |
Novarock Biotherapeutics Ltd. |
Payment unspecified |
3/28/18 |
June | ||||
4D Pharma and MSD to evaluate the combination of Keytruda and MRX-0518 in a phase I study for solid tumors |
4D Pharma plc |
Merck Sharp and Dohme Corp. |
Payment unspecified |
6/7/18 |
E-scape to develop and commercialize Abbvie's S1P5 agonists for lysosomal storage disorders worldwide |
Abbvie Inc. |
E-scape Bio |
Payment unspecified |
6/12/18 |
Abcellera and Denali to discover monoclonal antibodies with specific binding properties against a genetically validated target for neurodegenerative disease |
Abcellera Biologics Inc. |
Denali Therapeutics Inc. |
Payment unspecified |
6/12/18 |
Abcheck to discover multiple human single-chain variable fragments for Molmed's targets against liquid and solid tumors |
Abcheck s.r.o. |
Molmed SpA |
Payment unspecified |
6/28/18 |
Gossamer to develop and commercialize Aerpio's AKB-4924 and other structurally related products against inflammatory bowel disease, initially for ulcerative colitis and Crohn's disease worldwide |
Aerpio Pharmaceuticals Inc. |
Gossamer Bio Inc. |
$420.00 |
6/24/18 |
Cstone to develop and commercialize Agios' ivosidenib for acute myeloid leukemia and cholangiocarcinoma in mainland China, Hong Kong, Macau and Taiwan |
Agios Pharmaceuticals Inc. |
Cstone Pharmaceuticals Co. Ltd. |
$424.00 |
6/26/18 |
Bridgebio to acquire Alexion's ALXN-1101 for molybdenum cofactor deficiency Type A |
Alexion Pharmaceuticals Inc. |
Bridgebio Pharma LLC |
Unknown |
6/11/18 |
Akero Therapeutics to develop Amgen's AKR-001 against nonalcoholic steatohepatitis |
Amgen Inc. |
Akero Therapeutics |
Payment unspecified |
6/25/18 |
Aptus to design clinical study for Artelo's ART-27.13 against oncology |
Aptus Clinical Ltd. |
Artelo Biosciences Inc. |
Payment unspecified |
6/12/18 |
Infinity Pharmaceuticals and Arcus Biosciences to evaluate two triple combination therapies against triple negative breast cancer and ovarian cancer |
Arcus Biosciences Inc. |
Infinity Pharmaceuticals Inc. |
Unknown |
6/26/18 |
BB200 to license Arsanis' ASN-300 for preclinical development against Klebsiella pneumoniae infection worldwide with an option for clinical development and commercialization |
Arsanis Inc. |
BB200 LLC |
Payment unspecified |
6/14/18 |
Athenex to develop and commercialize Polytom's pegylated genetically modified human arginase for cancer worldwide |
Avalon Polytom Ltd. |
Athenex Inc. |
$50.00 |
6/29/18 |
Avella to distribute Array's combination therapy Braftovi and Mektovi for metastatic melanoma |
Avella |
Array Biopharma Inc. |
Payment unspecified |
6/28/18 |
Biologics to distribute Array's combination therapy Braftovi and Mektovi for metastatic melanoma |
Biologics Inc. |
Array Biopharma Inc. |
Payment unspecified |
6/29/18 |
Deinove and Biomerieux to discover antibiotics against bacterial infections |
Biomerieux SA |
Deinove SA |
Payment unspecified |
6/28/18 |
Goliver Therapeutics to use Biotime's pluripotent cell lines to advance therapeutic candidates against liver disease |
Biotime Inc. |
Goliver Therapeutics |
Payment unspecified |
6/25/18 |
BL&H to distribute Mediwound's Nexobrid for eschar removal in South Korea |
BL&H Co. Ltd. |
Mediwound Ltd. |
Payment unspecified |
6/4/18 |
Cstone Pharmaceuticals to develop and commercialize Blueprint Medicines' avapritinib, BLU-554 and BLU-667 in greater China |
Blueprint Medicines Corp. |
Cstone Pharmaceuticals Co. Ltd. |
$386.00 |
6/1/18 |
Brammer Bio to support the manufacture of Sarepta's gene therapy programs against Duchenne muscular dystrophy and limb girdle muscular dystrophy |
Brammer Biopharmaceuticals LLC |
Sarepta Therapeutics Inc. |
Payment unspecified |
6/13/18 |
Cannabics Pharmaceuticals and an undisclosed biopharmaceutical company to establish a new Israeli entity for treating eye disorders using cannabinoids |
Cannabics Pharmaceuticals Inc. |
Undisclosed |
Unknown |
6/29/18 |
Clovis Oncology to sign a letter of intent with Immunomedics for the evaluation of Rubraca with sacituzumab against metastatic triple-negative breast cancer and metastatic urothelial cancer |
Clovis Oncology Inc. |
Immunomedics Inc. |
Unknown |
6/3/18 |
Alexion and Complement to develop CP-010 for neurodegenerative disorders |
Complement Pharma |
Alexion Pharmaceuticals Inc. |
$17.20 |
6/11/18 |
CR Pharmaceutical to distribute Ascletis' Ganovo for hepatitis C in China |
CR Pharma |
Ascletis Pharmaceutical Co. Ltd. |
Payment unspecified |
6/26/18 |
Crownbio to provide services to accelerate Pierre-Fabre's immuno-oncology drug discovery |
Crown Bioscience Inc. |
Pierre-Fabre Research Institute |
Payment unspecified |
6/19/18 |
A. Menarini Asia-Pacific to commercialize Daiichi Sankyo's edoxaban in the Philippines, Malaysia and Singapore |
Daiichi Sankyo Co. Ltd. |
A. Menarini Asia-Pacific Holdings Pte. Ltd. |
Payment unspecified |
6/28/18 |
Apac Biotech to develop Diakonos Research's immunotherapy technology for solid tumors in India |
Diakonos Research Ltd. |
Apac Biotech Pvt. Ltd. |
Payment unspecified |
6/22/18 |
Tasly to develop and commercialize EA Pharma's AJT-240 for secondary hyperparathyroidism in China |
EA Pharma Co. Ltd. |
Tasly Pharmaceutical Group Co. Ltd. |
Payment unspecified |
6/12/18 |
Nico Innovapharma to sign a memorandum of understanding with Eastgate to commercialize insulin mouth rinse for type 2 diabetes in Europe |
Eastgate Biotech Corp. |
Nico Innovapharma |
$38.00 |
6/19/18 |
Cipla to distribute Lilly's Basaglar for type 1 and 2 diabetes in India |
Eli Lilly and Company (India) Pvt. Ltd. |
Cipla |
Payment unspecified |
6/8/18 |
Devonian Health to enter a letter of intent to develop Folia's FB-631 as an immunotherapeutic platform |
Folia Biotech Inc. |
Devonian Health Group Inc. |
Payment unspecified |
6/28/18 |
Taiwan Specialty Pharma to commercialize GNT's chidamide against breast cancer and peripheral T-cell lymphoma in Taiwan |
GNT Biotech and Medicals Corp. |
Taiwan Specialty Pharma Corp. |
$1.02 |
6/21/18 |
Lakepharma to use Harbour's H2L2 transgenic mouse platform for discovery of human antibodies |
Harbour Antibodies BV |
Lakepharma Inc. |
Payment unspecified |
6/5/18 |
Hookipa Biotech and Gilead Sciences to develop immunotherapies against human immunodeficiency virus and hepatitis B virus infections |
Hookipa Biotech AG |
Gilead Sciences Inc. |
$410.00 |
6/5/18 |
Horizon to grant manufacture and commercialization rights to Lupin for generic version of Ravicti in litigation settlement |
Horizon Pharma plc |
Lupin Ltd. |
Payment unspecified |
6/27/18 |
Iason to manufacture and distribute Blue Earth Diagnostics' positron emission tomography imaging product, Axumin to detect recurrence of prostate cancer in Poland |
Iason Sp. z o.o. |
Blue Earth Diagnostics Ltd. |
Payment unspecified |
6/25/18 |
Bionet-Asia and ICA to develop pentavalent DNA vaccine against dengue and Zika infection using Nanotaxi nanocarrier technology |
In-Cell-Art SAS |
Bionet-Asia Co. Ltd. |
Payment unspecified |
6/19/18 |
LG Chem to discover therapeutic oncology leads using Iontas' antibody discovery platforms |
Iontas Ltd. |
LG Chem Ltd. |
Payment unspecified |
6/5/18 |
Nicox and Ironwood Pharmaceuticals to identify therapeutics for the treatment of certain ophthalmic conditions |
Ironwood Pharmaceuticals Inc. |
Nicox SA |
Payment unspecified |
6/6/18 |
Isoplexis to evaluate the impact of Nektar's NKTR-214 against cancer using Isocode chip technology |
Isoplexis Corp. |
Nektar Therapeutics |
Payment unspecified |
6/26/18 |
Alliance Pharma to market Janssen's Nizoral, an anti-dandruff shampoo, in the Asia-Pacific region |
Janssen Pharmaceutica NV |
Alliance Pharma plc |
$83.47 |
6/19/18 |
Kramer Laboratories acquiring Nizoral from Janssen to treat dandruff |
Janssen Pharmaceutica NV |
Kramer Laboratories Inc. |
Payment unspecified |
6/25/18 |
Saladax Biomedical to use Janssen's patents related to companion diagnostics for antipsychotic medications worldwide |
Janssen Pharmaceutica NV |
Saladax Biomedical Inc. |
Payment unspecified |
6/26/18 |
Tersera Therapeutics to purchase Jazz Pharmaceuticals' Prialt for chronic pain |
Jazz Pharmaceuticals plc |
Tersera Therapeutics LLC |
$80.00 |
6/29/18 |
Novo Nordisk to develop and commercialize Kallyope's peptides for obesity and diabetes worldwide |
Kallyope Inc. |
Novo Nordisk A/S |
Payment unspecified |
6/19/18 |
Kangpu and Accelovance to evaluate KPG-121 in combination with enzalutamide in adults with metastatic castration-resistant prostate cancer |
Kangpu Biopharmaceuticals Inc. |
Accelovance Inc. |
Payment unspecified |
6/27/18 |
Kymab and Roche to evaluate KY-1044 in combination with atezolizumab against multiple tumors |
Kymab Ltd. |
F. Hoffmann-La Roche AG |
Payment unspecified |
6/28/18 |
Virpax to develop Lipocure's LBL-100 for pain using liposome drug delivery technology |
Lipocure Ltd. |
Virpax Pharmaceuticals Inc. |
Payment unspecified |
6/4/18 |
Nichi-Iko to distribute Lupin's etanercept against inflammatory conditions in Japan |
Lupin Ltd. |
Nichi-Iko Pharmaceutical Co. Ltd. |
Payment unspecified |
6/18/18 |
Mylan to commercialize Lupin's Enbrel biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most Asian markets |
Lupin Ltd. |
Mylan Inc. |
$15.00 |
6/28/18 |
Aytu to commercialize Magna's Zolpimist for insomnia in the U.S. and Canada |
Magna Pharmaceuticals Inc. |
Aytu Bioscience Inc. |
Payment unspecified |
6/11/18 |
Meiji Seika Pharma and Two Cells to discover a novel cell therapy for osteoarthritis |
Meiji Seika Pharma Co. Ltd. |
Two Cells Co. Ltd. |
Payment unspecified |
6/26/18 |
Microbiotica and Genentech to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease |
Microbiotica Ltd. |
Genentech Inc. |
$534.00 |
6/6/18 |
Hyundai to commercialize Mithra's Estelle as an oral contraceptive in South Korea |
Mithra Pharmaceuticals SA |
Hyundai Pharmaceutical Co. Ltd. |
Payment unspecified |
6/5/18 |
Orifarm to commercialize Mithra's Myring for contraception in Denmark |
Mithra Pharmaceuticals SA |
Orifarm Group A/S |
Payment unspecified |
6/21/18 |
Amarin and Mochida to develop and commercialize omega-3 acid eicosapentaenoic acid-based candidates against cardiovascular diseases in the U.S. and other territories |
Mochida Pharmaceutical Co. Ltd. |
Amarin Corp. plc |
$2.70 |
6/12/18 |
Mystic to manufacture East Gate's insulin mouth rinse solution for type 2 diabetes |
Mystic Pharmaceuticals Ltd. |
East Gate Pharmaceuticals |
Payment unspecified |
6/21/18 |
Fortify to develop Neurovive's NVP-015 for Leber's hereditary optic neuropathy |
Neurovive Pharmaceutical AB |
Fortify Therapeutics Inc. |
$60.00 |
6/18/18 |
Respirerx to enter a letter of intent with Noramco to co-develop and supply dronabinol against obstructive sleep apnea |
Noramco Inc. |
Respirerx Pharmaceuticals Inc. |
Payment unspecified |
6/13/18 |
TG Therapeutics and Novimmune to develop and commercialize TG-1801 for hematologic B-cell malignancies worldwide |
Novimmune SA |
TG Therapeutics Inc. |
$188 |
6/18/18 |
Oncobiologics to manufacture Sonnet's monoclonal antibodies |
Oncobiologics Inc. |
Sonnet Biotherapeutics Inc. |
Payment unspecified |
6/13/18 |
Erydel to develop Orphan Technologies' EE-TP for mitochondrial neurogastrointestinal encephalopathy using automated autologous red blood cell technology |
Orphan Technologies Ltd. |
Erydel SpA |
Payment unspecified |
6/4/18 |
Axovant to develop and commercialize Oxford's OXB-102 and its predecessor product Prosavin for Parkinson's disease worldwide |
Oxford Biomedica plc |
Axovant Sciences Ltd. |
$842.50 |
6/5/18 |
Nuance Biotech to develop and commercialize Pacira's Exparel for pain in China |
Pacira Pharmaceuticals Inc. |
Nuance Biotech Inc. |
$58.00 |
6/19/18 |
Pantherx to distribute Ultragenyx Pharmaceutical's Crysvita for X-linked hypophosphatemia |
Pantherx Specialty Pharmacy |
Ultragenyx Pharmaceutical Inc. |
Payment unspecified |
6/7/18 |
Pint Pharma to commercialize Pharmamar's Aplidin against hematological cancer in Latin America |
Pharmamar SA |
Pint Pharma GmbH |
Payment unspecified |
6/11/18 |
Phoremost and Oxygen Healthcare to develop drugs using siteseeker phenotypic screening platform |
Phoremost Ltd. |
Oxygen Healthcare |
Payment unspecified |
6/21/18 |
Premier Research to conduct phase III study for Infant Bacterial Therapeutics' IBP-9414 against necrotizing enterocolitis |
Premier Research Group Ltd. |
Infant Bacterial Therapeutics AB |
Payment unspecified |
6/26/18 |
Alvogen to commercialize Prestige Biopharma's HD-201 in Central and Eastern Europe |
Prestige Biopharma |
Alvogen Inc. |
Payment unspecified |
6/28/18 |
Ohara to develop, manufacture and commercialize Prism Pharma's PRI-724 injection for the treatment of fibrosis including cirrhosis in Japan |
Prism Pharma Co. Ltd. |
Ohara Pharmaceutical Co. Ltd. |
Payment unspecified |
5/24/18 |
Champions to develop patient derived xenograft tumor models for Puma's neratinib against metastatic breast and colon cancer |
Puma Biotechnology Inc. |
Champions Oncology Inc. |
Payment unspecified |
6/18/18 |
Recipharm divests Thyrosafe rights to Serb except in the U.S. |
Recipharm AB |
Serb SA |
$11.67 |
6/14/18 |
Redhill Biopharma to co-promote Napo's Mytesi against diarrhea in the U.S. |
Redhill Biopharma Ltd. |
Napo Pharmaceuticals Inc. |
Payment unspecified |
6/28/18 |
Zoetis to use Regeneron' VelocImmune technology to develop monoclonal antibodies against allergy, osteoarthritis and immune disorders |
Regeneron Pharmaceuticals Inc. |
Zoetis Inc. |
Payment unspecified |
6/6/18 |
Shionogi to develop and commercialize Sage's SAGE-217 for major depressive disorder in Japan, Taiwan and South Korea |
Sage Therapeutics Inc. |
Shionogi & Co. Ltd. |
$575.00 |
6/12/18 |
Salix to co-promote U.S. Worldmeds' Lucemyra for mitigation of opioid withdrawal symptoms in the U.S. |
Salix Pharmaceuticals Inc. |
U.S. Worldmeds LLC |
Payment unspecified |
6/26/18 |
Simbec-Orion to conduct a phase II study for Acticor Biotech's ACT-017 against acute ischemic stroke |
Simbec-Orion Group Ltd. |
Acticor Biotech |
Payment unspecified |
6/14/18 |
Skyhawk and Celgene to discover mRNA splicing modifiers using STAR* technology for neurological diseases with worldwide license option |
Skyhawk Therapeutics |
Celgene Corp. |
$60 |
6/26/18 |
EMS to distribute Sonoma Pharmaceuticals' dermatology products in Brazil |
Sonoma Pharmaceuticals Inc. |
EMS SA |
Payment unspecified |
6/4/18 |
Syngene to provide discovery and development services for Artelo Biosciences' ART27.13 against oncology |
Syngene International Ltd. |
Artelo Biosciences Inc. |
Payment unspecified |
6/12/18 |
Endo International to distribute Takeda's Colcrys 0.6 mg tablets against gout flares and Mediterranean fever in the U.S. |
Takeda Pharmaceutical Co. Ltd. |
Endo International plc |
Payment unspecified |
7/2/18 |
Isologic to manufacture Telix's TLX-250 for clinical trials in North America and commercialize it in Canada for the imaging of clear cell renal cell carcinoma |
Telix Pharmaceuticals Ltd. |
Isologic Innovative Radiopharmaceuticals Ltd. |
Payment unspecified |
6/25/18 |
Tesaro to divest North American rights of oral and intravenous formulations of Varubi to Tersera |
Tesaro Inc. |
Tersera Therapeutics LLC |
$60.00 |
6/28/18 |
Alvogen to distribute certain Theramex women's health products in Russia, Central and Eastern Europe as well as countries within the Commonwealth of Independent States |
Theramex |
Alvogen Inc. |
Payment unspecified |
6/25/18 |
Biogen to obtain an option to acquire TMS' TMS-007 and backup compounds for acute stroke |
TMS Co. Ltd. |
Biogen Inc. |
$357.00 |
6/7/18 |
Tonghua to manufacture and supply insulin lispro and insulin glargine active pharmaceutical ingredients to Adocia worldwide, excluding China |
Tonghua Dongbao Pharmaceutical Co. Ltd. |
Adocia SAS |
Payment unspecified |
6/1/18 |
Translate Bio and Sanofi to develop vaccines using mRNA technology for infectious diseases worldwide |
Translate Bio |
Sanofi SA |
$805.00 |
6/11/18 |
Straterx to use Trianni's Mouse to develop a fully human monoclonal antibody for oncology |
Trianni Inc. |
Straterx Inc. |
Payment unspecified |
6/12/18 |
U.S. Bioservices to distribute Rigel's Tavalisse tablets for immune thrombocytopenia in the U.S. |
U.S. Bioservices |
Rigel Pharmaceuticals Inc. |
Payment unspecified |
6/18/18 |
U.S. Bioservices to dispense Array Biopharma's binimetinib and encorafenib in the U.S. |
U.S. Bioservices Corp. |
Array Biopharma Inc. |
Payment unspecified |
6/28/18 |
Yakult Honsha to develop and commercialize Verastem's duvelisib for all oncology indications in Japan |
Verastem Oncology |
Yakult Honsha Co. Ltd. |
$100.00 |
6/5/18 |
Veritas Pharma and Foliumed to sign a memorandum of understanding for the development and commercialization of medical cannabis products |
Veritas Pharma Inc. |
Foliumed SAS |
Payment unspecified |
6/18/18 |
Wuxi to manufacture and develop Harbour's HCAbs against cancer |
Wuxi Biologics |
Harbour Biomed |
Payment unspecified |
6/24/18 |
Athenex and Xlifesc to establish a joint venture, Axis Therapeutics, to research, develop and commercialize T-cell receptor-engineered T-cell immunotherapies for cancer |
Xiangxue Life Science Research Center |
Athenex Inc. |
$5 |
6/29/18 |
July | ||||
Medimmune and 4DMT to design, develop and commercialize a gene therapeutic for patients with chronic lung disease |
4D Molecular Therapeutics LLC |
Medimmune LLC |
Payment unspecified |
7/10/18 |
Mylan to acquire intellectual property rights from Abbvie related to biosimilar adalimumab worldwide excluding Europe |
Abbvie Inc. |
Mylan Inc. |
Payment unspecified |
7/17/18 |
Trigr Therapeutics to develop and commercialize ABL Bio's antibodies for cancer worldwide excluding South Korea |
ABL Bio Inc. |
Trigr Therapeutics |
$554.30 |
7/2/18 |
Sandoz to commercialize Adamis' Symjepi for allergy including anaphylaxis in the U.S. |
Adamis Pharmaceuticals Corp. |
Sandoz Inc. |
Payment unspecified |
7/1/18 |
APC and Noria to test linker technology with Macropa radioisotope chelation technology in combination with antibodies for cancer |
Advanced Proteome Therapeutics Inc. |
Noria Pharmaceuticals Inc. |
Payment unspecified |
7/17/18 |
Sandoz to commercialize Aequus's Vistitan for glaucoma in Canada |
Aequus Pharmaceuticals Inc. |
Novartis AG |
Unknown |
7/16/18 |
Lynkogen to develop and commercialize Alteogen's GLP-1/A1AT fusion proteins against nonalcoholic steatohepatitis and metabolic diseases worldwide, excluding Korea |
Alteogen Inc. |
Lynkogen Inc. |
Payment unspecified |
7/1/18 |
Antoxerene and Juvenescence to form a joint venture, Foxbio to develop small molecule drugs for diseases of aging |
Antoxerene Inc. |
Juvenescence Ltd. |
Unknown |
7/12/18 |
Kalytera to acquire all rights of BPL's medical cannabis products worldwide |
Beetlebung Pharma Ltd. |
Kalytera Therapeutics Inc. |
$0.05 |
7/19/18 |
Axovant to develop and commercialize Benitec's BB-301 for oculopharyngeal muscular dystrophy worldwide |
Benitec Biopharma Ltd. |
Axovant Sciences GmbH |
$665 |
7/8/18 |
Bioagilytix and Bioasis to support and advance xB3-001 and define the clinical dose to treat HER2+ brain cancer |
Bioagilytix Labs LLC |
Bioasis Technologies Inc. |
Payment unspecified |
7/11/18 |
Prevacus to conduct a phase I clinical trial of PRV-002 using Blinktbi's Eyestat for concussion |
Blinktbi Inc. |
Prevacus Inc. |
Payment unspecified |
7/13/18 |
Corerx to manufacture Innovation Pharmaceuticals' brilacidin for oral mucositis |
Corerx Inc. |
Innovation Pharmaceuticals Inc. |
Payment unspecified |
7/17/18 |
Theramex to market Endoceutics' Intrarosa for vulvar and vaginal atrophy in postmenopausal women in Australia, Russia and selected countries in the Commonwealth of Independent States and Europe |
Endoceutics Inc. |
Theramex |
Payment unspecified |
7/19/18 |
Locus acquiring Epibiome's bacteriophage discovery platform to develop products, including ADJ-02, against antibiotic-resistant bacterial infections worldwide |
Epibiome Inc. |
Locus Biosciences |
Payment unspecified |
7/17/18 |
Serb Pharmaceuticals to acquire Eusa Pharma's critical care business including collatamp |
Eusa Pharma |
Serb Pharmaceuticals |
Payment unspecified |
7/11/18 |
Kite Pharma and Gadeta to develop gamma delta T-cell receptor therapies in various cancers, with an option to acquire Gadeta |
Gadeta BV |
Kite Pharma Inc. |
Payment unspecified |
7/19/18 |
Novartis to develop and commercialize Galapagos' MOR-106 for atopic dermatitis and other indications worldwide |
Galapagos NV |
Novartis AG |
$563.35 |
7/19/18 |
Biontech and Genevant Sciences to co-develop five mRNA therapeutic programs for rare diseases |
Genevant Sciences Ltd. |
Biontech AG |
Payment unspecified |
7/10/18 |
Genexine and Merck to conduct a phase Ib/II study to evaluate the combination of Hyleukin-7 with Keytruda for triple-negative breast cancer |
Genexine Co. Ltd. |
Merck & Co. Inc. |
Payment unspecified |
7/18/18 |
Dermavant to acquire Glaxosmithkline's tapinarof for psoriasis and atopic dermatitis worldwide except China, as well as back-up programs |
Glaxosmithkline plc |
Dermavant Sciences Inc. |
$340.12 |
7/12/18 |
Seqirus to commercialize Glenmark's Ryaltris for seasonal allergic rhinitis in Australia and New Zealand |
Glenmark Pharmaceuticals SA |
Seqirus Pty Ltd. |
Payment unspecified |
7/6/18 |
Gritstone to evaluate GRANITE-001 in combination with BMS' Opdivo and Yervoy against advanced solid tumor |
Gritstone Oncology |
Bristol-Myers Squibb Co. |
Payment unspecified |
7/19/18 |
Undisclosed major biopharmaceutical company to study GT Biopharma's OXS-1550 in combination with an oncology drug |
GT Biopharma Inc. |
Undisclosed |
Payment unspecified |
7/19/18 |
Highmark and Boehringer to collaborate on an outcomes-based contract related to Jardiance |
Highmark Inc. |
Boehringer Ingelheim International GmbH |
Payment unspecified |
7/10/18 |
Dare Bioscience to acquire patents related to Catsper ion channel from Hydra Biosciences |
Hydra Biosciences Inc. |
Dare Bioscience Inc. |
Payment unspecified |
7/16/18 |
Ibio to provide process development and manufacturing services to CC-Pharming to develop products including rituximab |
Ibio Inc. |
CC-Pharming Ltd. |
$4.70 |
7/9/18 |
Genmab and Immatics Biotechnologies to discover and develop next-generation bispecific cancer immunotherapies using Xpresident technology worldwide |
Immatics Biotechnologies GmbH |
Genmab A/S |
$1,704.00 |
7/12/18 |
Eusa Pharma to acquire worldwide rights to Janssen Sciences' Sylvant against idiopathic multicentric Castleman disease |
Janssen Sciences Ireland UC |
Eusa Pharma |
$115.00 |
7/18/18 |
Astellas Pharma and KM Biologics to market influenza hemagglutinin vaccine in Japan |
KM Biologics Co. Ltd. |
Astellas Pharma Inc. |
Payment unspecified |
7/2/18 |
Meiji Holdings and KM Biologics to market influenza hemagglutinin vaccine in Japan |
KM Biologics Co. Ltd. |
Meiji Holdings Co. Ltd. |
Payment unspecified |
7/2/18 |
Takeda to use Leon-Nanodrug's microjet reactor nano technology to assess and develop an innovative formulation from pipeline products |
Leon-Nanodrugs GmbH |
Takeda Pharmaceutical Co. Ltd. |
Payment unspecified |
7/17/18 |
Nissan Chemical and Luxna Biotech to discover and develop oligonucleotides therapeutics |
Luxna Biotech Co. Ltd. |
Nissan Chemical Corp. |
Payment unspecified |
7/6/18 |
Y-mabs to develop Mabvax's MV-NB-02 vaccine for neuroblastoma |
Mabvax Therapeutics Holdings Inc. |
Y-mabs Therapeutics Inc. |
$1.30 |
7/3/18 |
Vyriad to evaluate Voyager-V1 in combination with Merck's avelumab against metastatic colorectal cancer in a phase I clinical trial |
Merck KGaA |
Vyriad |
Payment unspecified |
7/18/18 |
Tasly to develop Mesoblast's MPC-150-IM and MPC-25-IC against chronic heart failure and acute myocardial infarction in China |
Mesoblast Ltd. |
Tasly Pharmaceutical Group Co. Ltd. |
$65.00 |
7/17/18 |
Zhuhai Essex to commercialize Mitotech's SkQ1 ophthalmic solution against dry eye disease and uveitis in Singapore and greater China |
Mitotech SA |
Zhuhai Essex Bio-Pharmaceutical Co. Ltd. |
Payment unspecified |
7/16/18 |
Novartis to develop and commercialize Morphosys' MOR-106 for atopic dermatitis and other indications worldwide |
Morphosys AG |
Novartis AG |
$563.35 |
7/19/18 |
Mundipharma to develop and commercialize Neovii's Grafalon for graft-versus-host disease in China and Japan |
Neovii Pharmaceuticals AG |
Mundipharma International Corp. Ltd. |
Payment unspecified |
7/5/18 |
Adlai Nortye Biopharma to develop and commercialize Novartis' buparlisib against cancer worldwide |
Novartis AG |
Adlai Nortye Pharmaceutical Co. Ltd. |
Payment unspecified |
7/10/18 |
Clinigen acquires worldwide rights o Novartis' Proleukin against metastatic renal cell carcinoma and metastatic melanoma excluding the U.S. |
Novartis AG |
Clinigen Group plc |
Payment unspecified |
7/17/18 |
Onco360 to distribute Array's combination therapy Braftovi and Mektovi for unresectable or metastatic melanoma |
Onco360 |
Array Biopharma Inc. |
Payment unspecified |
7/2/18 |
Terumo to commercialize Piramal's fentanyl injection for pain in Japan |
Piramal Critical Care Ltd. |
Terumo Corp. |
Payment unspecified |
7/5/18 |
Pluristem and Thermo Fisher to advance cell therapy industrialization and improve quality control of end-to-end supply chain |
Pluristem Therapeutics Inc. |
Thermo Fisher Scientific Inc. |
Payment unspecified |
7/9/18 |
Puretech and Roche to develop milk-derived exosome technology for the oral administration of antisense oligonucleotide |
Puretech Health plc |
Roche Holding AG |
$1,036.00 |
7/20/18 |
Shandong Danhong to develop Remd Biotherapeutics' REMD-288 and REMD-290 for cancer worldwide |
Remd Biotherapeutics Inc. |
Shandong Danhong Pharmaceutical Co. Ltd. |
$15.00 |
7/13/18 |
U.S.-based specialty pharma company to license Reneuron's human retinal progenitor cell technology and ReN-003 worldwide excluding China |
Reneuron Group plc |
Undisclosed |
$5.00 |
7/11/18 |
Sinovant to develop and commercialize Renexxion's naronapride in China, Hong Kong, Macau and Taiwan, initially for inflammatory bowel disease with constipation |
Renexxion |
Sinovant Sciences Ltd. |
Payment unspecified |
7/17/18 |
Sanofi and Revolution Medicines to develop and commercialize SHP2 inhibitors, including RMC-4630, for non-small-cell lung cancer and other cancers worldwide |
Revolution Medicines Inc. |
Sanofi SA |
$550.00 |
7/18/18 |
Shandong Danhong and Shanghai Yanyi to develop B-193 for lymphoma |
Shanghai Yanyi Biotechnology Co. Ltd. |
Shandong Danhong Pharmaceutical Co. Ltd. |
$10.46 |
7/13/18 |
STA to provide development and manufacturing services to Antengene's clinical stage and commercial oncology and viral drugs |
STA Pharmaceutical Co. Ltd. |
Antengene Corp. |
Payment unspecified |
7/16/18 |
Teneobio and Janssen to develop multi-specific antibodies for undisclosed oncology targets using the Unirat platform and the Teneoseek sequence-based discovery engine worldwide |
Teneobio Inc. |
Janssen Biotech Inc. |
Payment unspecified |
7/9/18 |
Tetra Bio-Pharma and Storz & Bickel to study PPP-001 in combination with Mighty Medic against fibromyalgia and other chronic pain conditions |
Tetra Bio-Pharma Inc. |
Storz & Bickel GmbH & Co. KG |
Payment unspecified |
7/16/18 |
Cure to sign a non-binding term sheet to acquire Therapix's cannabinoid-based drug pipeline |
Therapix Biosciences Ltd. |
Cure Pharmaceutical Inc. |
Payment unspecified |
7/11/18 |
TD2 to conduct preclinical studies for Atossa's chimeric antigen receptor T-cell therapy using intraductal microcatheter technology against breast cancer |
Translational Drug Development |
Atossa Genetics Inc. |
Payment unspecified |
7/18/18 |
Dr. Reddy's to co-promote and distribute UCB's Briviact for epilepsy in India |
UCB SA |
Dr. Reddy's Laboratories Ltd. |
Payment unspecified |
7/9/18 |
Wuxi to provide development and commercial manufacturing for Immune Pharmaceuticals' bertilimumab for bullous pemphigoid |
Wuxi Biologics |
Immune Pharmaceuticals Inc. |
Payment unspecified |
7/9/18 |
Stada and Xbrane to co-develop and commercialize Xlucane biosimilar for wet age-related macular degeneration in Europe, the U.S. and a variety of Middle East, North African and Asia Pacific markets |
Xbrane Biopharma AB |
Stada Arzneimittel AG |
$8.94 |
7/12/18 |
Xintela and Co.don to sign a letter of intent to establish a joint venture to develop a stem cell product for osteoarthritis in Europe and North America |
Xintela AB |
Co.don AG |
Unknown |
7/9/18 |
Zander and Ampersand to develop therapeutics for various disorders including arthritis, atopic dermatitis and cancer in companion animals |
Zander Therapeutics Inc. |
Ampersand Biopharmaceuticals Inc. |
Unknown |
7/5/18 |
|
Notes This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis. | ||||